ETFMG Alternative Harvest ETF
Most Recent
OrganiGram Stock Falls after Disappointing Q3 Earnings
Today, OrganiGram Holdings (NASDAQ:OGI) reported its third-quarter earnings. As expected, the results were disappointing.
What to Expect from OrganiGram’s Q3 Earnings
OrganiGram will likely report its third-quarter earnings before the market opens on July 21. Overall, there isn’t much hope.
Aphria Stock Rose More than 8% after Stifel’s Upgrade
Aphria (NYSE:APHA) received a bullish call from Stifel. On Monday, Stifel upgraded the stock from a “hold” to a “buy” rating.
Is Aphria or OrganiGram a Better Buy for Investors?
Analysts expect Aphria to report revenues of $631.8 million in the next four quarters. Management will focus on the medical and recreational sectors.
HEXO Enters Israel’s Medical Marijuana Market, Stock Surges over 18%
Today, HEXO announced that it launched its medical marijuana products in Israel. The company signed a two-year agreement with an Israeli cannabis company.
Curaleaf Holdings Completes Curaleaf NJ’s Acquisition
Curaleaf Holdings (OTCMKTS:CURLF) continued its expansion by completing the acquisition of Curaleaf NJ, which owns a medical license in New Jersey.
Aurora Cannabis Appoints New Chief Commercial Officer
As the demand for Cannabis 2.0 products continues to rise, Aurora Cannabis announced the appointment of Miguel Martin as its new chief commercial officer.
Curaleaf Plans a Nationwide Expansion of ‘Select’ Brand
Curaleaf (OTCMKTS:CURLF) acquired a “Select” brand in February 2020. The company received positive feedback in medical and adult-use markets.
Why Did Raymond James Downgrade OrganiGram?
On Monday, Cantech Letter reported that Raymond James downgraded OrganiGram from an “outperform” rating to a “market perform” rating.
Green Thumb Keeps Expanding Its Operations in Las Vegas
On June 27, Green Thumb Industries (OTCMKTS:GTBIF) opened its fifth Essence brand store in Las Vegas and its 48th retail store in the US.
Canopy Growth Announces Initiatives to Regain Market Share
In the fourth quarter, Canopy Growth (NYSE:CGC)(TSE:WEED) lost market share due to increased competition in value products.
Why Canadian Cannabis Sales Dipped Slightly in April
In April, cannabis sales came in at $180.1 million—0.6% down from the March sales. So, considering the spike in March, the sales weren’t disappointing.
MedMen’s Medical Marijuana Dispensary License Revoked in Virginia
The Virginia Board of Pharmacy voted not to extend MedMen’s conditional license to operate a medical marijuana dispensary in Staunton, Virginia.
Tilray Rebounded in Q1, Most Analysts Recommend a ‘Hold’
Tilray hasn’t reported a positive EBITDA yet. Analysts expect the company to become profitable in the first quarter of 2021.
Canopy Growth CEO Expects US to Legalize Cannabis by 2022
Amid the growing support for cannabis legalization, Canopy Growth (NYSE:CGC) CEO David Klein expects the federal government to legalize marijuana by 2022.
Top 2 Cannabis Stocks to Buy, Interest in the Sector Reignites
After underperforming the broader equity markets in the first quarter, the cannabis sector has been showing a strong recovery in the second quarter.
Curaleaf Expands Select Brand Medical Products in Connecticut
On Monday, Curaleaf Holdings announced that it will expand its Select brand products in Connecticut. The products will be available at medical dispensaries.
Canada’s Cannabis Oil Exports Rose More than 450% in 2019
Canada, with first-mover advantage, has been exploring new territories to export its cannabis oil. Last year, the company reported to 17 counties.
IIPR Acquires Another Property in Pennsylvania
Innovative Industrial Properties has continued its aggressive expansion. IIPR acquired a new property in Pennsylvania from Holistic Industries.
Illinois Reports Record Recreational Cannabis Sales in May
Illinois sold recreational cannabis worth $44.3 million in May—the highest amount since it legalized recreational sales in January this year.
Vireo Health Terminates Bruce Linton as Its Executive Chairman
On Monday, Vireo Health announced that it terminated Bruce Linton as its executive chairman immediately. He joined the company in November 2019.
Why California’s Legal Cannabis Sales Could Fall This Year
The budget proposed by Governor Gavin Newsom projected a decline in California’s cannabis sales. COVID-19 induced a recession in the US economy.
Closing Facility Could Cost Tilray $28 Million in Non-Cash Charges
On May 26, Tilray (NASDAQ:TLRY) announced that it will permanently shut down its High Park Gardens facility located in Leamington, Ontario.
Why Are Canadian Cannabis Companies Leaving Jamaica?
Canadian cannabis companies are frustrated by the Jamaican government’s inaction. They have decided to cut their losses and exit the Jamaican market.
Why OrganiGram Stock Rose More than 11% Yesterday
OrganiGram (NASDAQ:OGI) had good news for patients who use cannabis for medical purposes. The company expanded its medical cannabis offerings.
Why Canopy Growth Is a ‘Buy’ before Its Earnings
Despite the surge in May, Canopy Growth is still trading at a 54.3% discount from its 52-week high of $59.74. So, should you buy the stock?
Curaleaf: Analysts’ Recommendations after Its Q1 Earnings
Earlier this week, Curaleaf (OTCMKTS:CURLF) reported its first-quarter earnings. The company missed analysts’ revenue expectations.
Aurora Cannabis to Enter US CBD Market, Stock Rises over 30%
On Wednesday, Aurora Cannabis (NYSE:ACB) announced that it has signed an agreement to acquire Reliva—a US-based CBD company.
Why Did Curaleaf Report a Mixed Q1 Performance?
On Monday, Curaleaf (OTCMKTS:CURLF) reported its first-quarter earnings after the market closed. The company reported revenue of $96.5 million.
Why Curaleaf Is a ‘Buy’ before Its Q1 Earnings
Analysts expect Curaleaf’s EBITDA to rise during the quarter. They expect the company to report an EBITDA of $15.7 million.
Charlotte’s Web Reports Mixed Q1 Performance
Today, Charlotte’s Web reported a mixed first-quarter performance. For the quarter ended on March 31, the company reported revenues of $21.7 million.
GW Pharmaceuticals Stock Rises on Higher Epidiolex Sales
On Monday, GW Pharmaceuticals reported its first-quarter earnings. The company beat analysts’ revenue, EBITDA, and EPS expectations.
Tilray Posts Q1 Results, Stock Falls, and Net Losses Widen
On Monday, Tilray (NASDAQ:TLRY) reported its first-quarter earnings after the market closed. For the quarter, the company posted revenues of $52.1 million.
Why Did Aphria Stock Fall 7% on May 8?
On May 8, Aphria’s (NYSE:APHA) management announced that it agreed to repurchase its convertible senior notes from some holders outside of Canada.
Why Analysts Are Bullish before Charlotte’s Web’s Q1 Earnings
Charlotte’s Web Holdings (OTCMKTS:CWBHF)(NYSEARCA:CWEB) will likely report its first-quarter earnings before the market opens on May 14.
Tilray’s Q1 Earnings Could Boost Its Stock Price
The meltdown in global financial markets amid COVID-19 dragged Tilray stock down to $2.43 on March 18. Since then, the stock has recovered.
IIPR Stock Falls after Reporting Weak Q1 Performance
On May 6, Innovative Industrial Properties reported its first-quarter results after the market closed. The company posted an adjusted EPS of $0.72.
Why Has Aphria Risen in Today’s Pre-Trading Hours?
Today, Aphria (NYSE:APHA) announced that ASG Pharma has received EU GMP certification to produce cannabis for medical and research purposes.
Aphria Looks Attractive in the Cannabis Space
Aphria reported an adjusted EBITDA of $5.7 million in the third quarter. The company has reported a positive EBITDA for four consecutive quarters.
Should You Buy IIPR before Its Q1 Earnings?
IIPR will likely report its first-quarter earnings, which ended on March 31, after the market closes on May 6. So, should you buy the stock?
Why Is There Optimism before Cresco Labs’ Q4 Earnings?
Analysts expect Cresco Labs to report revenue of $43.7 million in the fourth quarter—YoY growth of 157.9% from $17.0 million in the fourth quarter of 2018.
Why Did Canopy Growth Stock Rise on Monday?
Canopy Growth (NYSE:CGC)(TSE:WEED) stock rose to a high of 22.66 Canadian dollars before closing at 21.46 Canadian dollars on Monday.
Canopy Growth to Exit Africa, Close Another Canadian Facility
Canopy Growth announced another set of global operational changes to optimize its production, improve efficiency, and align its supply with the demand.
Why Analysts Had Mixed Reactions to Aphria’s Q3 Earnings
On April 14, Aphria (NYSE:APHA) reported its third-quarter earnings. For the quarter, the company reported revenues of 144.4 million Canadian dollars.
Comparing Canopy Growth and Aurora Cannabis’s Valuation Multiples
Canopy Growth and Aurora Cannabis are two prominent players in the cannabis sector. So far in 2020, Canopy Growth has outperformed cannabis ETFs.
Will Aphria’s Q3 Earnings Lift the Cannabis Sector?
Analysts expect Aphria to report revenue of 130.6 million Canadian dollars in the third quarter—growth of 77.5% YoY and a sequential increase of 8.3%.
OrganiGram to Reduce Workforce by 45% Due to COVID-19
OrganiGram has joined the list of cannabis companies, like Canopy Growth and Aurora Cannabis, that will reduce their workforce.
Bruce Linton: WEED and CRON Can Handle COVID-19 Storm
On April 6, Bruce Linton said that Canopy Growth (TSE:WEED) and Cronos Group (NASDAQ:CRON) are better equipped to withstand the COVID-19 storm.
Comparing OrganiGram and Aphria’s Valuation Multiples
So far this year, OrganiGram Holdings (NASDAQ:OGI) and Aphria (NYSE:APHA) have lost 11.0% and 36.7% of their stock price.
3 Cannabis Stocks Investors Should Watch as Markets Rebound
As the markets start to rebound, three cannabis stocks could deliver strong returns. Cannabis sales have increased amid the coronavirus outbreak.
Curaleaf Reports Impressive Q4 Earnings Results
On Tuesday, Curaleaf (OTCMKTS:CURLF) reported its fourth-quarter earnings after the market closed. The company reported revenue of $75.46 million.
OrganiGram Receives Expansion License from Health Canada
On Monday, OrganiGram Holdings (NASDAQ:OGI) announced that it received a license from Health Canada to expand its Phase 5.
Cannabis Stocks Outperformed Broader Equity Markets Last Week
Last week was the worst week since October 2008. However, the cannabis sector fared better than the broader equity markets.
Will Curaleaf Beat Analysts’ Expectations in Q4?
Curaleaf Holdings (OTCMKTS:CURLF) will report its fourth-quarter earnings after the market closes on March 24. Analysts are bullish on Curaleaf.
Why Did Bank of America Upgrade Aphria and OrganiGram?
On March 19, Bank of America upgraded Aphria (NYSE:APHA) and OrganiGram Holdings (NASDAQ:OGI) due to the increased demand for cannabis.
What to Expect from Charlotte’s Web’s Q4 Earnings
Charlotte’s Web Holdings (NYSEARCA:CWEB) will report its earnings for the fourth quarter of 2019 before the market opens on March 24.
Roth Capital Initiates Coverage on IIPR with a ‘Buy’ Rating
On March 16, Roth Capital initiated coverage on Innovative Industrial Properties (NYSE:IIPR) with a “buy” rating and a stock price of $110.
Will the Fed’s Rate Cut Help Marijuana Stocks?
The marijuana sector saw a sharp decline last week amid the global sell-off. The S&P 500 fell by 8.8% in the week ending on March 13.
Analysts Recommend a ‘Buy’ for Curaleaf before Its Q4 Earnings
As of Thursday, nine analysts covered Curaleaf. Among the analysts, eight recommend a “buy,” while one recommends a “hold.”
Alabama Gets Closer to Legalizing Medical Marijuana
On Thursday, WBRC reported that the Alabama Senate cleared Senate Bill 165. The bill will create the Compassion Act, which legalizes medical marijuana.
IIPR Looks Promising amid Struggling Cannabis Sector
As of March 11, Innovative Industrial Properties (NYSE:IIPR) was trading at $76.96—a rise of 1.4% since the beginning of this year.
Stifel Initiated Its Coverage on Aphria and HEXO
On Tuesday, MarketWatch reported that Stifel initiated its coverage on Aphria and HEXO. Stifel gave Aphria a “hold” and HEXO a “sell” rating.
Canopy Growth Will Close Facilities and Cut Jobs
Yesterday, Canopy Growth (NYSE:CGC)(TSE:WEED) announced that it’s optimizing its operations to align its supply based on demand.
Charlotte’s Web Reports Improved Yield and CBD Potency
On Wednesday, Charlotte’s Web Holdings (NYSEARCA:CWEB) announced that the audit of its 2019 hemp harvest is complete.
How Will Curaleaf Benefit from Acquiring BlueKudu?
On Monday, Curaleaf (OTCMKTS:CURLF) announced that it will acquire BlueKudu—a company that produces premium cannabis chocolates and gummies.
Should You Consider Buying Canopy Growth?
As of February 28, Canopy Growth (NYSE:CGC)(TSE:WEED) was trading at 25.17 Canadian dollars. So far, the company has lost 7.8% of its stock value YTD.
Should You Consider Buying Aurora Cannabis?
On Thursday, Aurora Cannabis hit a 52-week low of 1.80 Canadian dollars and closed at 1.95 Canadian dollars. ACB has lost 30.1% of its stock value this year.
Why Did Cowen Downgrade Aurora Cannabis?
On Monday, MarketWatch reported that Cowen downgraded Aurora Cannabis from “outperform” to “market perform” and lowered the target price.
Alabama’s Senate Committee Clears Medical Marijuana Bill
The Senate Judiciary Committee of Alabama cleared the bill that legalizes medical marijuana in the state. The committee voted 8-1 in favor of the proposed legislation.
What to Expect from Green Growth Brands’ Q2 Earnings?
Green Growth Brands will likely report its results for the second quarter of fiscal 2020 on February 24. Analysts expect the company’s revenue to rise sequentially.
Kentucky’s House Committee Clears Medical Marijuana Bill
Kentucky’s House Judiciary Committee cleared House Bill 136, which legalizes medical marijuana. The committee cleared the bill in favor of a 17-1 vote.
Can Canopy Growth’s Q3 Earnings Lift the Cannabis Sector?
On Friday, Canopy Growth will report its third-quarter earnings before the market opens. Investors will be watching the results closely.
Will Ontario Have Marijuana Lounges and Cafes Soon?
Ontario’s government started collecting input from the public about allowing marijuana consumption in lounges and cafes across the province.
Why Kentucky Residents Favor Marijuana Legalization
More Kentucky residents favor marijuana legalization. According to a poll, 90% of the respondents favor medical marijuana compared to 78% in 2012.
Illinois Sold Nearly $40 Million of Cannabis in January
The Chicago Tribune reported that customers spent $39.2 million on recreational cannabis in Illinois the first month after legalization.
What Drove Aurora Cannabis Stock Yesterday?
On Monday, Aurora Cannabis announced that its Aurora River production facility received EU GMP certification. The facility is located in Bradford, Ontario.
Cannabis Tax Collection Falls below Expectations
Canada legalized recreational cannabis on October 17, 2018. However, cannabis hasn’t met the government’s expected revenue collection.
Why Are Hemp Prices Still Falling?
Farmers expected high earnings from hemp cultivation. However, hemp prices have fallen. Farmers are struggling to find enough buyers.
Illegal Sales Continue to Haunt Cannabis Companies
On January 23, Statistics Canada announced that the average price of marijuana increased in the fourth quarter. The illegal marijuana price also increased.
Cresco Labs Stock Rose after Securing $100 Million Loan
On Thursday, Cresco Labs announced that it signed an agreement for a senior secured term loan for an initial aggregate principal amount of $100 million.
Why Is Aphria’s EU GMP Certification a Big Deal?
Yesterday, Aphria announced that it received GMP (Good Manufacturing Practices) certification from the EU for its subsidiary Avanti Rx Analytics.
Is Charlotte’s Web Still a Good Buy?
Although 2019 was tough for Charlotte’s Web Holdings, it has made a significant recovery this year. The stock has increased by 14.8% YTD as of Monday.
Why Is Cowen Still Bullish on Aurora Cannabis?
Cowen reiterated its “buy” rating for Aurora Cannabis (NYSE:ACB). The investment firm maintained its target price of 6 Canadian dollars.
Will the New CBD Bill Boost US Businesses?
For CBD products, federal regulation could take years. However, the situation might change with the introduction of Collin Peterson’s new bill.
Comparing APHA and OGI’s Valuation Multiples
As of Wednesday, Aphria (NYSE:APHA) was trading at a forward EV-to-sales multiple of 2.38x. The valuation multiple increased despite the lower stock price.
Can Curaleaf Maintain Its Upward Momentum?
Acquisitions could boost Curaleaf’s production and retail footprint significantly. With the EBITDA expected to rise over the next two years, there’s significant upside.
Big News: Cannabis Edibles in Alberta Stores
Many people expected the Cannabis 2.0 products, including cannabis edibles, to hit the markets by mid-December 2019. However, the products got delayed.
Has HEXO Stock Bottomed Out?
On January 10, HEXO was trading at 1.74 Canadian dollars, a fall of 63.1% since the beginning of 2019 and a discount of 84.6% to its 52-week high.
GW Pharmaceuticals Provides Preliminary Sales Update
On January 12, GW Pharmaceuticals announced its preliminary unaudited product sales report for the fourth quarter and 2019.
What Do Analysts Recommend for KushCo Holdings?
KushCo Holdings reported its Q1 earnings on January 8. KushCo reported revenue of $34.96 million, below analysts’ forecast of $41.5 million.
Why Cannabis Stocks Are Trading in the Red Today
Driven by weakness in the US equity market, the cannabis sector was down today. Payrolls grew by 2.9%, which is below analysts’ estimate of 3.1%.
Aurora Cannabis Gets a Price Target of $1
Yesterday, MarketWatch reported that Piper Sandler had downgraded its rating for Aurora Cannabis (NYSE:ACB) to “sell” from “hold.”
IIPR: How to Invest in Cannabis and Still Make Money
While cannabis investors lost a lot of wealth last year, one stock continued to deliver staggering returns—Innovative Industrial Properties (IIPR).
Why Are Cannabis Stocks Trading Higher Today?
Boosted by a strong broader US equity market, the cannabis sector was trading in the green today. Here are the cannabis stocks making big moves.
Cannabis in Illinois—An Update after the First Week
In June 2019, Illinois legalized adult-use cannabis, becoming the 11th state to do so. It was the first state to legalize marijuana through the legislature.
OrganiGram’s First-Quarter Earnings: What to Expect
Yesterday, OrganiGram stock was trading at 2.68 Canadian dollars, 23.4% lower than when the company reported its fourth-quarter earnings on November 25.
Why Cannabis Stocks Are Falling Today
Weakness in cannabis stocks continued today, the fourth day of decline. The US equity market fell today due to the growing tension between the US and Iran.
Is GW Pharmaceuticals a Good Bet?
Analysts expect GW Pharmaceuticals to become profitable in 2020. They expect the company’s EBITDA to be $42.8 million in 2020.
Cannabis Sector Marks Third Straight Day of Decline
The downward momentum in cannabis stocks has continued today, marking the third straight day of decline for the cannabis sector.
Joe Biden Wants More Research on Vaping
Democratic nominee Joe Biden thinks e-cigarette sales should only be allowed after scientific analysis of the products’ long-term impact on health.